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complications, necrotizing vasculitis and exacer- 
bation of a pre-existing psoriasis, after use of G-CSF 
for treatment of a small cell lung cancer. 
A 45year-old woman was treated for a limited 
small cell lung cancer with a chemotherapy regimen 
consisting of cyclophosphamide (1 g m ~ 2), doxo- 
rubicin (50 mg m ~ ‘), cisplatin (100 mg m - 2), and 
etoposide (200 mg mp2). Because the patient had 
febrile neutropenia after the first course of chemo- 
therapy, she was treated with 3OOpg day-’ of 
G-CSF subcutaneously on days 3-10 following the 
end of the second course of chemotherapy. Four days 
later, she developed palpable purpuric lesions on the 
legs characteristic of a necrotizing vasculitis, and we 
observed exacerbation of psoriasis over thorax and 
legs. No biopsy was done as clinical aspects were 
rather characteristic. 
There were no antibodies detected for nuclear 
cytoplasm antigens, hepatitis B and C viruses or 
human immunodefiency virus. Cryoglobulinemia and 
proteinuria were absent. The leucocyte count was 
3.5 x lo9 1~ ’ with 2.8 x lo9 l- ’ neutrophils; plate- 
lets were 211 x lo9 I- r. Treatment with topical cor- 
ticosteroid resolved psoriasis within 10 days, and 
purpuric lesions disappeared in about the same time. 
Considering the relative severity of the cutaneous 
lesions, the patient did not receive further G-CSF. 
Two additional courses with cisplatin and etoposide 
were administered simultaneously with thoracic 
radiotherapy, without recurrence of the cutaneous 
adverse effects. 
Large reports of G-CSF treated patients with 
small cell lung cancer have been reported without 
cutaneous adverse effects (1,2). However, one patient 
with small cell lung cancer developed pyoderma 
gangraenosum during G-CSF therapy, and another 
patient showed necrotizing vasculitis with 
granulocyte-macrophage stimulating factor (3,4). Six 
other cases of cutaneous vasculitis have been 
reviewed in patients with various tumours, treated 
with leucocyte colony-stimulating factors. The erup- 
tions are unrelated to the primary diseases and 
developed after 1 or 2 weeks of therapy. It is inter- 
esting that exacerbation of psoriasis has been noted 
in a patient with aplastic anemia subsequent to 
granulocyte macrophage-stimulating factor (5). To 
our knowledge, our case report is the first with both 
vasculitis and psoriasis. The mechanisms by which 
G-CSF exacerbate pre-existing psoriasis or induce 
vasculitis remain unknown. Various cytokines may 
be an indirect cause (tumour necrosis factor, 
interleukin-1) (6). We conclude that patients and 
physicians should be aware of the development 
of various inflammatory processes during G-CSF 
treatment. Patients with pre-existing psoriasis should 
be treated with caution, while receiving G-CSF. 
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Dear Editor 
Gallbladder wall thickening as a sign of pulmonary 
embolism 
Alvarez-Sala et al. described a patient with acute 
pulmonary embolism, in whom thickening of the 
gallbladder wall was shown by abdominal sonogra- 
phy (1). The authors suggest that this could be an 
initial sign of increased cystic and systemic venous 
hypertension, due to right cardiac failure, and hence 
to acute pulmonary embolism. The validity of the 
sign, however, is not established, since other cases 
have not been reported (2). We wish to report a case 
of acute pulmonary embolism we have observed, in 
which this sign was present. 
A 92-year-old woman was admitted because of 
vomiting and tachycardia of several days duration. 
She denied dyspnoea and thoracic or abdominal 
pain. The remaining history was unremarkable. 
Blood pressure was 120/90 mmHg, heart rate was 
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84 beats min - ‘, and respiratory rate was 20 breaths 
min- ‘. The findings from cardiopulmonary and 
abdominal examination were normal. There were 
no signs of deep venous thrombosis in the 
lower extremities. The aspartate aminotransferase 
was 9001U ll’, the lactate dehydrogenase was 
25241U l-‘, the y-glutamyl-transpeptidase was 
68 IU l- ‘, the alkaline phospatase was 196 IU 1 - ‘, 
and the total bilirubin was 1.03 mg dl ~ ‘. A chole- 
cystitis was suspected and abdominal sonography 
was performed, which demonstrated marked thicken- 
ing of the gallbladder wall, with double appearance, 
and some hypoechoic lamellae within the wall. These 
signs are considered to be very suggestive of acute 
acalculous cholecystitis (3). Arterial gasometry 
revealed a PO, of 67.2 mmHg and a PCO, of 
24.8 mmHg, with an alveoloarterial oxygen gradient 
of 48.8. The chest radiograph was normal, and an 
ECG showed sinus rhythm, right atria1 enlargement, 
and an incomplete right bundle branch block. Since 
the patient did not show clinical signs of acute 
cholecystitis, we hypothesized a pulmonary embol- 
ism. There were biochemical signs of consumption of 
coagulation factors (thrombocytopenia, prolonged 
PT and PTT, reduced fibrinogen level, and elevated 
fibrin degradation products). Pulmonary perfusion 
scintigraphy showed some segmental defects. 
Treatment with heparin was started. Three weeks 
later, biochemical data and gas analysis were normal, 
and the abdominal sonogram indicated that the 
gallbladder wall was normal. 
Thickening of the gallbladder wall is a sign 
suggestive of cholecystitis, but it has poor speci- 
ficity, because there are many causes of gallbladder 
thickening. Oedema associated with congestive heart 
failure results in an absolutely identical appearance 
to that of inflammation (3). In cases of pulmonary 
embolism, the thickening of the gallbladder wall 
may be due to right cardiac failure and increased 
venous pressure. Our case confirms that reported by 
Alvarez-Sala et al. (1). Therefore, we think that the 
thickening of the gallbladder wall could be an initial 
sign of pulmonary embolism, although unusual. The 
presence of this sign in pulmonary embolism must 
be considered in order to avoid wrong diagnoses. 
However, its frequency needs further study. 
V. FORESTI 
III Medical Department 
Fatebenefratelli Hospital 
Milan 
Italy 
19 September 1994 
References 
1. Alvarez-Sala R, Caballero P, Garcia-Rio F, Prados C, 
Alvarez-Sala JL. Gallbladder wall thickening. A new 
diagnostic sign of acute pulmonary embolism. Chest 
1993; 103: 319-320. 
2. Stein PD. Reply to: Gallbladder wall thickening. Chest 
1993; 103: 320. 
3. Weill FS. Ultrasound Diagnosis of Digestive Discuses, 
(3rd ed.). Berlin: Springer-Verlag, 1990: 341. 
